Abstract：Objective: To investigate the effect of Metformin combined with Ethinyl Estradiol Cyproterone in the treatment of polycystic ovary syndrome (PCOS). Methods: 90 PCOS cases in our hospital from January 2017 to January 2018 were randomly divided into control group (oral Ethinylestradiol Cycloprogesterone) and observation group (oral Ethinylestradiol Cycloprogesterone + Metformin) by the random number table with simple randomization method, 45 cases in each group, corresponding treatment was given. The clinical data of the two groups were recorded .Serum galactose lectin - 3 (Galectin - 3) level, sex hormones, blood lipid, fasting blood sugar, insulin levels and other indicators of the patients were measured before and after treatment. Results: Before treatment, there was no significant difference between the observation group and the control group (P>0.05). After treatment, the difference before and after treatmentthe of body mass index (BMI), waist-to-hip ratio (WHR), Galectin-3 level, luteinizing hormone (LH), testosterone (T), estradiol (E2), triglyceride (TG), high-density lipoprotein (HDL),low-density lipoprotein (LDL) and fasting serum glucose (FPG), fasting insulin (FINS), homeostasis model assessment-insulin resistance index (HOMA-IR) and ovulation rate and pregnancy rate were significantly higher than those of the control group, abortion rate was significantly lower than those of the control group, and the difference were statistically significant (P<0.05). There were no significant differences in the difference between follicle stimulating hormone (FSH) and total cholesterol (TC) in the observation group and the control group (P>0.05). Conclusion: Metformin combined with Ethinyl Estradiol Cyproterone has a good therapeutic effect on PCOS,which can effectively regulate sex hormone levels and alleviate insulin resistance.
[1] Mahalingaiah S,Diamanti-Kandarakis E.Targets to treat metabolic syndrome in polycystic ovary syndrome[J].Expert Opin Ther Targets,2015,19(11):1561~1574. [2] Stefano M, Carla I, Claudia BF, et al. Role of galectin-3 in obesity and impaired glucose homeostasis[J].Oxid Med Cell Longev,2015,2016(33):1~7. [3] Shi X, Xie X, Jia Y, et al. Associations of insulin receptor and insulin receptor substrates gen- etic polymorphisms with polycystic ovary syndrome:A systematic review and meta-analysis[J].Obstet Gynaecol Res, 2016, 42 (7):844~854. [4] Dumitrescu R, Mehedintu C, Briceag I,et al. The polycystic ovary syndrome :an update on metabolic and hormonal mechanisms[J].J Med Life,2015 , 8 (2):142~145. [5] Zafari Zangeneh F, Naghizadeh MM, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers[J]. Int Reprod Biomcd (Yazd), 2017, 15 (6):375~382. [6] Kriseman M, Mills C, Kovanci E, et al.Antimullerian hormone levels are inversely associated with body miss index (BMI) in women with polycystic ovary Syndrome[J].Assist Reprod Genet,2015,32(9):1313~1316. [7] Homburg R, Gudi A, Shah A, et al. A novel method to demonstrate that pregnant women with polycystic ovary syndrome hyper-expose their fetus to androgens as a possible stepping stone for the developmental theory of PCOS.A pilot study[J].Reprod Biol Endocrino1,2017,15 (1):61. [8] Baravalle M E,Stassi A F,Velazquez M M,et al.Altered expression of pro-inflammatory cytokines in ovarian follicles of crows with cystic ovarian disease[J].Comp Pathol,2015,153 (2~3):116~130. [9] Kalem MN, Kalem Z, Gurgan T.Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles [J].Endocrinol Invest,2017,40 (7):745~752. [10] Li P,Liu S, Lu M,et al.Hematopoietic-derived galectin-3 Causes cellular and systemic insulin resistance[J].Cell, 2016,167(4):973.
2020, Vol. 26 
冀公网安备13080202000677号